BioTalk is a news hub brought to you by Bird & Bird's International Life Sciences & Healthcare Group. Read more about us >

New 2019 French Patent/Software box regime: taxation at a reduced rate of 10%

Biotech 1 min
February 7, 2019

A new preferential taxation regime for income generated by industrial property and software is applicable since January 1, 2019.

This new regime, applicable either to types of intangible assets or to a family of products or services, provides taxation at a reduced rate of 10% of net income generated by industrial property including patents and non-patented patentable inventions (for European SME only) and also copyrighted software. The inclusion of software constitutes the major change to the taxation regime.

The net income basis subject to a reduced rate of 10%, vs 31% in 2019, takes into account the research costs (which could also qualify for the Research Tax Credit) and a percentage determined from the “nexus” approach (i.e. ratio between the qualified costs and the total costs including the purchase cost).

This new regime also involves a detailed documentation that should be provided to the French Tax Authorities the first day of the tax audit under a penalty corresponding to 5% of income generated from the non-documented intangible asset.

Written by
Laurence Clot
Laurence Clot
As head of Bird & Bird's Tax Group in France, I am specialised in providing truly international tax advice to clients, particularly in respect of significant transactions.
Alexandre Polak
Alexandre Polak
I am a Counsel in our Tax Group in Paris. I specialise in providing national and international tax advice to our clients, offering significant expertise in M&A, restructuring and private equity as well as in individual tax matters.

Related articles

COVID-19: Our series of regulatory legislation trackers for the Life Sciences & Healthcare industry
COVID-19 presents an unprecedented challenge to the global life sciences industry.  Members...
Investing in the future of cannabis in the UK – lessons from the German model
The excitement around the potential for the UK cannabis market – medicinal and nutritional – to continue...
Cookie consent
We use analytics cookies to help us understand if our website is working well and to learn what content is most useful to visitors. We also use some cookies which are essential to make our website work. You can accept or reject our analytic cookies (including the collection of associated data) and change your mind at any time. Find out more in our Cookie Notice.